TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02988245
Drug: JNC-8
Normalized name: FACTOR VIIA,RECOMBINANT-JNCW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using JNC-8 guidelines to guide therapy
Study: NCT06538844
Drug: Intravenous infusion of human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
Study: NCT05478720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of saline
Study: NCT05032183
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05032183
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05032183
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05032183
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT06335303
Drug: Placebo matching BI 1819479
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1819479
Study: NCT05427162
Drug: Prostacyclin Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin receptor agonist will be administered.
Study: NCT05996627
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06247488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive oral dose of placebo.
Study: NCT05672173
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06083883
Drug: NY-ESO-1 TCR/IL-15 NK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT06083883
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT06226571
Drug: Chemotherapy Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
Study: NCT06226571
Drug: HiDAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation: Participants will receive HiDAC IV.
Study: NCT05328297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules will be administered orally.
Study: NCT06213649
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Study: NCT05411718
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05638633
Drug: Prednisolone 20 mg/ 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
Study: NCT05638633
Drug: Placebo for Vitamin B compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo for vitamin B compound placebo for 28 days.
Study: NCT06236139
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04944290
Drug: Simbrinza 0.2%/1% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product
Study: NCT05107999
Drug: Zhizhu Kuanzhong capsules (ZZKZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FD patients were treated with ZZKZ and omeprazole for 4 weeks.
Study: NCT05262218
Drug: PBF-680 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBF-680 10mg administered orally once a day
Study: NCT05262218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once a day
Study: NCT05028153
Drug: Azithromycin Oral Liquid Product
Normalized name: azithromycin Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg for 3 consecutive days
Study: NCT03644706
Drug: ADV7103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
Study: NCT03644706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules.
Study: NCT04837235
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05288504
Drug: AVTX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 600 mg administered subcutaneously three times during the study.
Study: NCT05288504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sourced as normal saline administered subcutaneously three times during the study.
Study: NCT04607837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study: NCT06721052
Drug: Postoperative analgesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
Study: NCT06785012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06720597
Drug: Testosterone therapy as per clinical guidelines.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
Study: NCT05110742
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05110742
Drug: CAR.5/IL15-transduced CB-NK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT04767802
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepcidin mimetic
Study: NCT05677893
Drug: MBS-COV
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
Study: NCT06625320
Drug: RMC-6236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT06625320
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT06373731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive once daily SC doses of Placebo 96 weeks
Study: NCT06478225
Drug: BGT007H Cell Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28).
Study: NCT06363877
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline.
Study: NCT05798117
Drug: YTB323
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of YTB323
Study: NCT06052267
Drug: TEV-56248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
Study: NCT05600036
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05600036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05594563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice a day
Study: NCT04939883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
Study: NCT05475769
Drug: Clinical evaluation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
Study: NCT06036797
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
Study: NCT05004805
Drug: Saline nasal spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
Study: NCT04873297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 ml of plain water Via NG
Study: NCT06006832
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining low-dose oral steroids
Study: NCT05557253
Drug: Balanced Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
Study: NCT05005338
Drug: BIIB122 (DNL151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses
Study: NCT06031441
Drug: RO7566802
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7566802 solution for infusion will be administered as specified in each treatment arm.
Study: NCT05544539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
Study: NCT06088862
Drug: Nicorette 4Mg Chewing Gum
Normalized name: Nicorette 4mg Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
Study: NCT06088862
Drug: Nicorette Lozenge Product
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
Study: NCT05879991
Drug: BI 1810631 (C-14) formulation 1
Normalized name: TRIOLEIN, 1-C-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1810631 (C-14) formulation 1
Study: NCT06707090
Drug: TR987 0.1% gel + Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
Study: NCT04630145
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive CAM 400 or 500 mg twice a day.
Study: NCT04743453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
Study: NCT05076955
Drug: vancomycin-tobramycin-itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Study: NCT04752774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder and solvent for solution for injection
Study: NCT06331533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl was injected into the placebo side
Study: NCT05039801
Drug: Glutaminase-1 Inhibitor IACS-6274
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06083922
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1, 8 and 15, Cycles 1-8
Study: NCT06161805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 hour infusion with saline (NaCl 0.9%)
Study: NCT06039189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as subcutaneous injection.
Study: NCT06041178
Drug: 2.5% flurbiprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
Study: NCT06041178
Drug: 98% aloe vera
Approvals — FDA: no, EMA: no, PMDA: no
Description: the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
Study: NCT05311774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT05740969
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cream
Study: NCT05740969
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cream
Study: NCT04258488
Drug: Vitamin K antagonist(warfarin)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 12months, keep the international normalized ratio (INR) 1.7-3.0
Study: NCT05670353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
Study: NCT05769153
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Needleless syringe used to simulate an intravitreal injection
Study: NCT06226025
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
Study: NCT04756063
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vitamin C
Study: NCT05662215
Drug: Placebo for CK-3828136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for CK-3828136
Study: NCT05400226
Drug: VGT-309
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
Study: NCT06159114
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Study: NCT06159114
Drug: Celecoxib capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
Study: NCT06159114
Drug: Ningmitai placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
Study: NCT06159114
Drug: Celecoxib placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
Study: NCT06646211
Drug: Methotrexate , Thiotepa and Zanubrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21
Study: NCT06561256
Drug: Janus Kinase Inhibitor
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janus Kinase Inhibitor in combination with corticosteroids
Study: NCT05023304
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study: NCT05023304
Drug: Topical Prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care topical drop treatment
Study: NCT06195540
Drug: Low Heparin Molecular Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Study: NCT05719285
Drug: Multi-Dose Antibiotic
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses
Study: NCT05532618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of sodium chloride 0.9%
Study: NCT04662723
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: To reduce the progression of renal damage in IgAN Patients
Study: NCT05205005
Drug: Endocalyx
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,712mg (six capsules) of DSGP for eight weeks.
Study: NCT05205005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
Study: NCT05652504
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
Study: NCT06484829
Drug: Purinostat Mesylate 4 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.